MS drug rejected over cost to HSE

Multiple Sclerosis (MS) Ireland says it is disappointed that an expert group failed to recommend a life-changing drug be made available through the HSE because it costs too much.

Wed, 21 Jan, 2015 - 00:00

Gordon Deegan

The National Centre for Pharmaeconomics (NCPE) report found the total lifetime costs for Tecfidera to the HSE are an estimated €226,738 per patient.

The tablet provides an alternative to painful injection for patients with the common form of the disease.

CONNECT WITH US TODAY

NEWSLETTERS

NOTIFICATIONS

Be the first to know the latest news and updates

More in this section

AI prompt chat bot. Search website to generate data, text or image. Man using computer with artificial intelligence app. Virtual

Mental health experts issue warning over AI 'therapy'

Spinal care taskforce has not met in over six months

Mourners at Amy Doherty’s funeral hear of her ‘magnetic personality’

Courts Place: Ireland Person: CEO Person: Ava Battles Organisation: MS Organisation: HSE Organisation: Sclerosis Organisation: MS) Ireland Organisation: National Centre for Pharmaeconomics Organisation: NCPE Organisation: Tecfidera Organisation: MS Ireland

<p>The chapel doors close for the final time on Michael Lyster pictured this evening at the funeral of former RTÉ radio and TV broadcaster. Picture: Colin Keegan, Collins, Dublin.</p>

Michael Lyster remembered as ‘magic in human form’ at emotional memorial service

READ NOW

MS drug rejected over cost to HSE

Michael Lyster remembered as ‘magic in human form’ at emotional memorial service

Lunchtime News

Latest

MS drug rejected over cost to HSE

Continue reading for €5

Michael Lyster remembered as ‘magic in human form’ at emotional memorial service

Lunchtime News

Latest

Most Read